OSE Immunotherapeutics SA and the FoRT Foundation(Fondazione Ricerca Traslazionale) announced that the first patient has been randomized in the Phase 2 clinical trial evaluating Tedopi? in combination with Opdivo? or chemotherapy as second-line treatment in patients with metastatic non-small cell lung cancer (NSCLC). This three-arm Phase 2 study will evaluate neo-epitope-based vaccine Tedopi? in combination with Bristol Myers Squibb?s Opdivo? (nivolumab), an immune checkpoint inhibitor, or Tedopi? plus chemotherapy or chemotherapy alone as second-line treatment in patients with HLA-A2 positive metastatic NSCLC after first-line chemo-immunotherapy.